DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center - WO66-G609
Silver Spring, MD 20993-0002

January 11, 2017

Aerin Medical, Inc.
Scott Wolf, M.D.
President and Chief Medical Officer
690 W. Fremont Avenue, Unit 3
Sunnyvale, CA 94087

Re: K162810
Trade/Device Name: InSeca ARC Stylus, Aerin Console
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical Cutting and Coagulation Device and Accessories
Regulatory Class: Class II
Product Code: GEI
Dated: December 9, 2016
Received: December 12, 2016

Dear Dr. Wolf:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Eric A. Mann -S

for Malvina B. Eydelman, M.D.
Director
Division of Ophthalmic and Ear,
Nose and Throat Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*

K162810

Device Name

InSeca ARC Stylus and Aerin Console

Indications for Use *(Describe)*

InSeca ARC Stylus

The InSeca ARC Stylus is indicated for use in otorhinolaryngology (ENT) surgery for the coagulation of soft tissue in the nasal airway, to treat nasal airway obstruction by shrinking submucosal tissue.

Aerin Console

The Aerin Console is an electrosurgical system intended to generate radiofrequency electrical current for the use of an ARC Stylus (e.g., InSeca ARC Stylus). The Aerin Console is indicated for use in small clinic, office or hospital environments.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

This 510(k) Summary is being submitted in accordance with the requirements of 21 CFR 807.92.

General Information

Submitter Information	
Company:	Aerin Medical, Inc.
Submitter's Address:	232 E. Caribbean Drive Sunnyvale, CA 94089
Contact Person:	Scott Wolf, M.D. President and Chief Medical Officer Phone: 650-434-3247 Fax: 408-716-2438
Establishment Registration Number	3011625895
Date Prepared:	December 9, 2016
Name of the Device	
Proprietary Name:	InSeca ARC Stylus, Model FG256 Aerin Console, Model FG226
Common Name:	Radiofrequency generator and probe
Classification Name:	Electrosurgical cutting and coagulation device and accessories
Classification Panel:	General and Plastic Surgery
Device Class:	Class II
Product Code:	GEI
CFR Section:	21 CFR 878.4400
Predicate Device:	Aerin Medical Stylus (K161994)
Reference Device:	Smith & Nephew ORA-50™ S Radiofrequency Generator (K993854)
Device Description	
InSeca ARC Stylus The InSeca ARC Stylus is a handheld bipolar radiofrequency (RF) probe designed for use in otorhinolaryngology (ENT) surgery. The Stylus comprises a handle, shaft and treatment tip. The treatment tip consists of an array of bipolar electrodes and a temperature sensor that allows for monitoring of tissue temperature during RF energy delivery. The Stylus is designed for use with the Aerin Console. It includes	

features to allow compatibility with and authentication by the Aerin Console. The Stylus connects to the Aerin Console via a flexible cable.

The InSeca ARC Stylus is used to treat patients experiencing chronic nasal airway obstruction. During a treatment procedure, the clinician inserts the tip of the InSeca ARC Stylus into a patient's nostril to deliver low power RF energy to the target tissue of the nasal airway. Radiofrequency treatment of tissue creates a coagulative lesion which fibroses and retracts as it heals, thereby shrinking the tissue to lessen the degree of obstruction.

Aerin Console

The Aerin Console is an RF generator designed to be used with the InSeca ARC Stylus to deliver bipolar RF energy to tissue. The Aerin Console consists of an RF generator, a power cord, and a foot switch. It incorporates user interface software to control, monitor and regulate RF power delivery to soft tissues via a cable-connected electrosurgical hand piece and electrode.

Indications for Use

InSeca ARC Stylus

The InSeca ARC Stylus is indicated for use in otorhinolaryngology (ENT) surgery for the coagulation of soft tissue in the nasal airway, to treat nasal airway obstruction by shrinking submucosal tissue.

Aerin Console

The Aerin Console is an electrosurgical system intended to generate radiofrequency electrical current for the use of an ARC Stylus (e.g., InSeca ARC Stylus). The Aerin Console is indicated for use in small clinic, office or hospital environments.

Summary of the technological characteristics of the device compared to the predicate device

The InSeca ARC Stylus and Aerin Console were found to be equivalent to the predicate device in design and intended use to generate and deliver bipolar RF energy to coagulate tissue in ENT procedures.

Characteristic	**InSeca ARC Stylus (Model FG256) and Aerin Console (Model FG226) Subject Device**	**Aerin Medical Stylus (Model FG174) - K161994 Predicate Device**
Design configuration	Same	Integrated cable, handle and electrode
Energy type	Same	Bipolar radiofrequency
Tissue temperature	Same	50 – 70 °C (temperature controlled)

Stylus RF generator compatibility	Aerin Console, Model FG226	Smith & Nephew ORA-50 S
Use limit feature	Yes	No
Characteristic	**Aerin Console (Model FG226) Subject Device**	**Smith & Nephew ORA-50 S (K993854) Reference Device**
Design configuration	Same	Generator, power cord, foot switch
Energy type	Same	Bipolar radiofrequency
Operating frequency (KHz)	Same	460
Treatment temperature range	50-70°C	15-99°C
Output power	3-5 watts	Up to 50 watts
Stylus validation feature	Yes	No

Summary of non-clinical tests

Device performance testing included bench testing, software validation and usability testing. Force load testing was conducted to verify adequate shaft strength. The efficacy of the subject device is supported by thermocouple accuracy and response time testing via water bath immersion and tissue heating time testing. Tissue heating time testing was performed using tissues representative of the submucosal tissues of the nasal airway. The subject devices met all the performance testing requirements. Additional performance testing was performed to verify substantial equivalence to the predicate devices in terms of thermal effects. The testing showed that the InSeca ARC Stylus used with the Aerin Console creates thermal lesion volumes that are comparable to volumes created with the predicate device.

Device safety is supported through biocompatibility testing, sterilization and packaging validation activities, electrical safety testing and electromagnetic compatibility testing. Biocompatibility of the InSeca ARC Stylus was demonstrated through testing performed in accordance with AAMI/ANSI/ISO 10993-1 (2009/(R) 2013). The sterilization validation was performed in accordance with ANSI/AAMI/ISO 11135:2014 and ISO 10993-7:2008. Electrical safety of the Aerin Console and InSeca ARC Stylus was demonstrated through testing to IEC 60601-1:2005/A1:2012 and IEC 60601-2-2:2009 and electromagnetic compatibility testing was performed according to IEC 60601-1-2:2007/AC:2010. The InSeca ARC Stylus packaging system was subjected to transit testing, visual inspection, accelerated aging, gross leak detection and seal strength testing in accordance with the applicable ASTM standards (ASTM D4169-14, ASTM F1980-07, ASTM F2096-11, and ASTM F88/F88M-15), and met all acceptance criteria.

Summary of clinical tests
Not applicable. No clinical tests were necessary.
Conclusion
Testing demonstrates that the InSeca ARC Stylus and Aerin Console are substantially equivalent to the predicate in terms of both indications for use and delivered RF treatment and is as safe and effective for its intended use.